EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.

@article{Scher2013EGFRmutatedLC,
  title={EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.},
  author={Kevin S Scher and Juan-Sebastian Saldivar and Michael Fishbein and Alberto M. Marchevsky and Karen L Reckamp},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2013},
  volume={11 9},
  pages={1040-4}
}
This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Histologic transformation of non-small-cell lung cancer in brain metastases

Meng Jiang, X Zhu, +4 authors X Ding
International Journal of Clinical Oncology • 2018

References

Publications referenced by this paper.
Showing 1-10 of 23 references

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth Case Report Scher et al © JNCCN—Journal of the National Comprehensive Cancer Network

GD Goss, I Lorimer, MS Tsao
J Clin Oncol 2010;28(Suppl):Abstract LBA7005 • 2013

Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: comparison between T790M mutation-positive and -negative populations [abstract

A Hata, N Katakami, H Yoshioka
J Clin Oncol • 2012

Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2011

with activating EGFR mutations in malignant effusion and cerebrospinal fluid : rapid and sensitive detection of exon 19 deletion E 746 - A 750 and exon 21 L 858 R mutations by immunocytochemistry

A Hata, N Katakami, H Yoshioka
2011

Similar Papers

Loading similar papers…